RxDoctor Payments Data

Howard Kreger, MD

Neurology · Concord, NCNPI 1174529879

Payments from drug & device makers

$80,185in general payments, 2019–2025

Across 192 payments — averaging $417.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$63K
  • AbbVie$12K
  • Medtronic$2K
  • Livanova USA, Inc.$1K
  • Biohaven Pharmaceutical Holding Company Ltd.$449
  • Teva Pharmaceuticals USA, Inc.$174
  • plus $948 from 18 others

What the payments were for

  • Speaking & faculty fees$10,94471%
  • Travel & lodging$2,15214%
  • Food & beverage$2,21014%
  • Education$1671%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,185 in reported general payments places this provider in the 80th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$102,984
Medicare patients
330
Services billed
5,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate111$149,982
UbrelvyUbrogepant96$137,458
AustedoDeutetrabenazine18$123,813
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$103,789
QuliptaAtogepant83$95,480
Emgality PenGalcanezumab-Gnlm74$55,976
Aimovig AutoinjectorErenumab-Aooe39$39,541
AptiomEslicarbazepine Acetate20$24,950
Emgality SyringeGalcanezumab-Gnlm27$23,448
NeuproRotigotine18$17,607
Carbamazepine ErCarbamazepine52$6,107
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone26$6,019
Levetiracetam127$5,916
Gabapentin259$5,463
Oxcarbazepine101$5,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$12,017$232,938179 claims
PfizerNurtec Odt$99$149,982111 claims
Teva Pharmaceuticals USA, Inc.Austedo$174$123,81318 claims
Sunovion Pharmaceuticals Inc.Aptiom$21$24,95020 claims
UCB, Inc.Neupro$25$17,60718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 566 neurology providers in North Carolina.

Other neurology in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →